These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12607597)

  • 1. Relationship between the thymidine labeling and Ki-67 proliferative indices in 126 breast cancer patients.
    Molino A; Pedersini R; Micciolo R; Frisinghelli M; Giovannini M; Pavarana M; Nortilli R; Santo A; Manno P; Padovani M; Piubello Q; Cetto GL
    Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):304-9. PubMed ID: 12607597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis.
    Rudas M; Gnant MF; Mittlböck M; Neumayer R; Kummer A; Jakesz R; Reiner G; Reiner A
    Breast Cancer Res Treat; 1994; 32(2):165-75. PubMed ID: 7865846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
    Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
    J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis.
    Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S
    J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of visual assessment and image analysis in the evaluation of Ki-67 expression and their prognostic significance in immunohistochemically defined luminal breast carcinoma.
    Arihiro K; Oda M; Ohara M; Kadoya T; Osaki A; Nishisaka T; Shiroma N; Kobayashi Y
    Jpn J Clin Oncol; 2016 Dec; 46(12):1081-1087. PubMed ID: 27511992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic values of proliferative markers ki-67 and repp86 in breast cancer.
    Mohsenifar J; Almassi-Aghdam M; Mohammad-Taheri Z; Zare K; Jafari B; Atri M; Mortazavi SH; Azadeh P; Bagherzadeh M; Azargashb E; Rahimi F
    Arch Iran Med; 2007 Jan; 10(1):27-31. PubMed ID: 17198450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidine labeling index: prognostic role in breast cancer.
    Bilir A; Ozmen V; Kecer M; Eralp Y; Cabioglu N; Ahishali B; Camlica H; Aydiner A
    Am J Clin Oncol; 2004 Aug; 27(4):400-6. PubMed ID: 15289735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters.
    Buck A; Schirrmeister H; Kühn T; Shen C; Kalker T; Kotzerke J; Dankerl A; Glatting G; Reske S; Mattfeldt T
    Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1317-23. PubMed ID: 12271413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 (MIB1), p53, and Lewis-X (LeuM1) as prognostic factors of recurrence in T1 and T2 laryngeal carcinoma.
    Sittel C; Eckel HE; Damm M; von Pritzbuer E; Kvasnicka HM
    Laryngoscope; 2000 Jun; 110(6):1012-7. PubMed ID: 10852523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
    Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
    Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases.
    Rudolph P; MacGrogan G; Bonichon F; Frahm SO; de Mascarel I; Trojani M; Durand M; Avril A; Coindre JM; Parwaresch R
    Breast Cancer Res Treat; 1999 May; 55(1):61-71. PubMed ID: 10472780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer.
    Silvestrini R; Daidone MG; Valagussa P; Di Fronzo G; Mezzanotte G; Mariani L; Bonadonna G
    J Clin Oncol; 1990 Aug; 8(8):1321-6. PubMed ID: 2380758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thymidine labeling index in breast tumors.
    Lee HD; Soh EY; Chi HS; Kim BR; Lee KS; Song KS; Jung HJ
    Jpn J Surg; 1990 Mar; 20(2):180-5. PubMed ID: 1692890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index.
    Kurozumi S; Matsumoto H; Hayashi Y; Tozuka K; Inoue K; Horiguchi J; Takeyoshi I; Oyama T; Kurosumi M
    BMC Cancer; 2017 May; 17(1):354. PubMed ID: 28532429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative activity of primary breast cancer and of synchronous lymph node metastases evaluated by [3H]-thymidine labelling index.
    Daidone MG; Silvestrini R; Valentinis B; Persici P; Mezzanotte G; Squicciarini P; Orefice S; Salvadori B
    Cell Tissue Kinet; 1990 Sep; 23(5):401-8. PubMed ID: 2245439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer.
    Rudolph P; Alm P; Heidebrecht HJ; Bolte H; Ratjen V; Baldetorp B; Fernö M; Olsson H; Parwaresch R
    J Natl Cancer Inst; 1999 Feb; 91(3):271-8. PubMed ID: 10037106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIB-1 proliferative activity in invasive breast cancer measured by image analysis.
    Querzoli P; Albonico G; Ferretti S; Rinaldi R; Magri E; Indelli M; Nenci I
    J Clin Pathol; 1996 Nov; 49(11):926-30. PubMed ID: 8944614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of the Tritiated Thymidine Labeling Index in breast cancers.
    Araki K; Kimura M; Sakamoto K; Nishimura R; Akagi M
    Jpn J Surg; 1985 Mar; 15(2):144-9. PubMed ID: 4010096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.